Strain Name:

NOD.129P2(B6)-Ctsbtm1Jde/RclJ

Stock Number:

008051

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Common Names: NOD.Catb;    
This congenic NOD strain contains a neomycin cassette that disrupts exon 4 of cathepsin B (Ctsbtm1Jde). NOD Ctsb deficient mice exhibit modestly delayed diabetes onset. This model provides a tool for detailed studies to identify the molecular pathways of major lysosomal cysteine proteases, specifically cathepsin B, in immune modulation.

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse
Background Strain NOD
Donor Strain 129P2/OlaHsd (E14.1 ES cells)
H2 Haplotypeg7
GenerationN11pN1
Generation Definitions
 
Donating InvestigatorDr. Renee C LeBoeuf,   Universtiy of Washington

Description
Mice homozygous for the Ctsb targeted mutation are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities. Northern blot analysis of kidney total RNA indicates a lack of transcript in homozygous mutant mice. An absence of Ctsb protein in homozygous mutant mice was determined by Western blot analysis of kidney lysosomal protein extracts. The proteolytic activity of the endogenous protein was found to be absent using an assay involving liver lysosomal extracts, obtained from homozygous mutant mice, and a fluorogenic substrate (Halangk et al. 2000).

The donating investigator indicates that the diabetes incidence in homozygous mutant NOD mice is significantly reduced (28%) compared to wildtype NOD (69%), while heterozygous mice are modestly protected from diabetes (50%) at six months of age. Histological analysis of the pancreas from non-diabetic homozygous mice indicate that insulitis is present but at much lower levels than in diabetic homozygous mice. Heterozygous mice had severe insulitis, indicating that the loss of one Ctsb allele is associated with delayed diabetes onset. Thyroiditis and sialadentis scores of mutant and NOD mice are equivalent. Data collected indicates that the loss of Cathepsin B delays but does not halt diabetes onset.

This model provides a tool for detailed studies focused on the identification of the molecular pathways of major lysosomal cysteine proteases, specifically cathepsin B, in immune modulation.

Development
The Cathepsin B gene, located on Chromosome 14, 63.7Mb, was disrupted via homologous recombination in 129P2/OlaHsd-derived, E14.1 ES cells. A neomycin cassette was inserted into a BglII site in exon 4; which introduced a premature stop codon into the open reading frame of the Ctsb gene. The resulting ES cell clone was injected into C57BL/6 blastocysts. The chimeric founder's offspring were bred to C57BL/6J prior to 10 generations of crossing to NOD and intercrossing. Marker assisted analysis indicate 19 known Idd loci which are of NOD origin. In 2008, the T1DR received this strain at generation N11F2.

Control Information

  Control
   001976 NOD/ShiLtJ
 
  Considerations for Choosing Controls

Related Strains

Alzheimer's Disease Models
005987   129-Achetm1Loc/J
006409   129S1.129(Cg)-Tg(APPSw)40Btla/Mmjax
008077   129S1/Sv-Bchetm1Loc/J
016198   129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ
014556   129S6/SvEv-Apoetm4Mae/J
006555   A.129(B6)-Tg(APPSw)40Btla/Mmjax
005708   B6.129-Apbb1tm1Quhu/J
004714   B6.129-Bace1tm1Pcw/J
004098   B6.129-Klc1tm1Gsn/J
004193   B6.129-Psen1tm1Mpm/J
003615   B6.129-Psen1tm1Shn/J
005300   B6.129-Tg(APPSw)40Btla/Mmjax
005617   B6.129P-Psen2tm1Bdes/J
002609   B6.129P2-Nos2tm1Lau/J
007685   B6.129P2-Psen1tm1Vln/J
007999   B6.129P2-Sorl1Gt(Ex255)Byg/J
008087   B6.129S1-Bchetm1Loc/J
002509   B6.129S2-Plautm1Mlg/J
005301   B6.129S2-Tg(APP)8.9Btla/J
004163   B6.129S4-Cdk5r1tm1Lht/J
010959   B6.129S4-Grk5tm1Rjl/J
010960   B6.129S4-Grk5tm2Rjl/J
002213   B6.129S4-Ngfrtm1Jae/J
006406   B6.129S4-Tg(APPSwLon)96Btla/Mmjax
006469   B6.129S4-Tg(PSEN1H163R)G9Btla/J
012564   B6.129S5-Dhcr24tm1Lex/SbpaJ
004142   B6.129S7-Aplp2tm1Dbo/J
004133   B6.129S7-Apptm1Dbo/J
007251   B6.129X1-Mapttm1Hnd/J
013040   B6.Cg-Apoetm1Unc Ins2Akita/J
005642   B6.Cg-Clutm1Jakh/J
005491   B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
009126   B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
005866   B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax
008730   B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
005864   B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
007575   B6.Cg-Tg(CAG-Ngb,-EGFP)1Dgrn/J
016197   B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J
005855   B6.Cg-Tg(Camk2a-Prkaca)426Tabe/J
007004   B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ
004996   B6.Cg-Tg(DBH-Gal)1923Stei/J
007673   B6.Cg-Tg(Gad1-EGFP)3Gfng/J
004662   B6.Cg-Tg(PDGFB-APP)5Lms/J
006293   B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2Mmjax
006006   B6.Cg-Tg(Prnp-APP)A-2Dbo/J
008596   B6.Cg-Tg(Prnp-Abca1)EHol/J
006005   B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax
007180   B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J
007182   B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J
005999   B6.Cg-Tg(SBE/TK-luc)7Twc/J
012597   B6.Cg-Tg(Thy1-COL25A1)861Yfu/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
009337   B6.FVB-Tg(Prnp-RTN3)2Yanr/J
006394   B6;129-Apba2tm1Sud Apba3tm1Sud Apba1tm1Sud/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
008476   B6;129-Ncstntm1Sud/J
004807   B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax
007605   B6;129P-Psen1tm1Vln/J
005618   B6;129P2-Bace2tm1Bdes/J
008333   B6;129P2-Dldtm1Ptl/J
002596   B6;129P2-Nos2tm1Lau/J
003822   B6;129S-Psen1tm1Shn/J
012639   B6;129S4-Mapttm3(HDAC2)Jae/J
012869   B6;129S6-Apbb2tm1Her/J
006410   B6;129S6-Chattm2(cre)Lowl/J
005993   B6;129S6-Pcsk9tm1Jdh/J
008636   B6;C-Tg(Prnp-APP695*/EYFP)49Gsn/J
007002   B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax
008169   B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J
000231   B6;C3Fe a/a-Csf1op/J
008850   B6;SJL-Tg(Mt1-LDLR)93-4Reh/AgnJ
003378   B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J
004462   B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
016556   B6N.129-Ptpn5tm1Pjlo/J
018957   B6N.129S6(B6)-Chattm2(cre)Lowl/J
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
006554   B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax
012621   C.129S(B6)-Chrna3tm1.1Hwrt/J
002328   C.129S2-Plautm1Mlg/J
003375   C3B6-Tg(APP695)3Dbo/Mmjax
005087   C57BL/6-Tg(Camk2a-IDE)1Selk/J
005086   C57BL/6-Tg(Camk2a-MME)3Selk/J
008833   C57BL/6-Tg(Camk2a-UBB)3413-1Fwvl/J
007027   C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax
010800   C57BL/6-Tg(Thy1-PTGS2)300Kand/J
010703   C57BL/6-Tg(Thy1-PTGS2)303Kand/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
007677   CB6-Tg(Gad1-EGFP)G42Zjh/J
007072   CByJ.129P2(B6)-Nos2tm1Lau/J
006472   D2.129(B6)-Tg(APPSw)40Btla/Mmjax
007067   D2.129P2(B6)-Apoetm1Unc/J
013719   D2.Cg-Apoetm1Unc Ins2Akita/J
003718   FVB-Tg(GadGFP)45704Swn/J
013732   FVB-Tg(NPEPPS)1Skar/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ
002329   FVB.129S2-Plautm1Mlg/J
003753   FVB/N-Tg(Eno2CDK5R1)1Jdm/J
006143   FVB/N-Tg(Thy1-cre)1Vln/J
008390   STOCK Apptm1Sud/J
012640   STOCK Hdac2tm1.2Rdp/J
004808   STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
004779   STOCK Mapttm1(EGFP)Klt/J
014092   STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
View Alzheimer's Disease Models     (109 strains)

Additional Web Information

Visit the Alzheimer's Disease Mouse Model Resource site for helpful information on Alzheimer's Disease and research resources.

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Ctsbtm1Jde/Ctsb+

        NOD.129P2-Ctsbtm1Jde
  • immune system phenotype
  • decreased susceptibility to autoimmune diabetes
    • 50% of female mice exhibit blood glucose levels of greater than 250 mg/dl between 4-6 months of age as compared to 69% of NOD controls   (MGI Ref ID J:153355)
  • insulitis
    • insulitis scores for diabetic animals are similar to diabetic NOD controls   (MGI Ref ID J:153355)
  • homeostasis/metabolism phenotype
  • hyperglycemia   (MGI Ref ID J:153355)
  • endocrine/exocrine gland phenotype
  • insulitis
    • insulitis scores for diabetic animals are similar to diabetic NOD controls   (MGI Ref ID J:153355)

Ctsbtm1Jde/Ctsbtm1Jde

        NOD.129P2-Ctsbtm1Jde
  • immune system phenotype
  • decreased susceptibility to autoimmune diabetes
    • hyperglycemia in females occurs at a lower percentage and later incidence than NOD controls   (MGI Ref ID J:153355)
  • insulitis
    • diabetic animals develop insulitis, however, lymphocytic infiltration is less than diabetic NOD controls   (MGI Ref ID J:153355)
  • salivary gland inflammation
    • sialadenitis is observed in both diabetic and non-diabetic mice at 6 months of age; average number of lesions observed is similar to number found in NOD mice   (MGI Ref ID J:153355)
  • homeostasis/metabolism phenotype
  • hyperglycemia   (MGI Ref ID J:153355)
  • endocrine/exocrine gland phenotype
  • insulitis
    • diabetic animals develop insulitis, however, lymphocytic infiltration is less than diabetic NOD controls   (MGI Ref ID J:153355)
  • salivary gland inflammation
    • sialadenitis is observed in both diabetic and non-diabetic mice at 6 months of age; average number of lesions observed is similar to number found in NOD mice   (MGI Ref ID J:153355)
  • digestive/alimentary phenotype
  • salivary gland inflammation
    • sialadenitis is observed in both diabetic and non-diabetic mice at 6 months of age; average number of lesions observed is similar to number found in NOD mice   (MGI Ref ID J:153355)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Immunology, Inflammation and Autoimmunity Research
Autoimmunity
      Type 1 Diabetes

Neurobiology Research
Alzheimer's Disease

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Ctsbtm1Jde
Allele Name targeted mutation 1, Jan Deussing
Allele Type Targeted (Null/Knockout)
Common Name(s) CTSB-; Cat B-; CathB-;
Mutation Made ByDr Jan Deussing,   Max-Planck-Institute of Psychiatrie
Strain of Origin129P2/OlaHsd
ES Cell Line NameE14.1
ES Cell Line Strain129P2/OlaHsd
Gene Symbol and Name Ctsb, cathepsin B
Chromosome 14
Gene Common Name(s) APPS; CB; CPSB;
General Note in combination with Ctsltm1Cptr, double homozygous mutant have some similarities but distinct phenotypic characteristics compared to the human syndrome: neuronal ceroid lipofuscinoses (NLCs)
Molecular Note A neomycin selection cassette was inserted into a BglII site in exon 4. Northern blot analysis of total RNA showed a lack of transcript in homozygous mutant mice. An absence of protein in homozygous mutant mice was determined by Western blot analysis of kidney lysosomal protein extracts. The proteolytic activity of the endogenous protein was found to be absent using an assay involving liver lysosomal extracts obtained from of homozygous mutant mice and a fluorogenic substrate. [MGI Ref ID J:64872]

Genotyping

Genotyping Information

Genotyping Protocols

Ctsbtm1Jde, Separated PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Deussing J; Roth W; Saftig P; Peters C; Ploegh HL; Villadangos JA. 1998. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci U S A 95(8):4516-21. [PubMed: 9539769]  [MGI Ref ID J:47432]

Halangk W; Lerch MM; Brandt-Nedelev B; Roth W; Ruthenbuerger M; Reinheckel T; Domschke W; Lippert H; Peters C; Deussing J. 2000. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 106(6):773-81. [PubMed: 10995788]  [MGI Ref ID J:64872]

Hsing LC; Kirk EA; McMillen TS; Hsiao SH; Caldwell M; Houston B; Rudensky AY; Leboeuf RC. 2009. Roles for cathepsins S, L, and B in insulitis and diabetes in the NOD mouse. J Autoimmun :. [PubMed: 19664906]  [MGI Ref ID J:153355]

Additional References

Ctsbtm1Jde related

Baran K; Ciccone A; Peters C; Yagita H; Bird PI; Villadangos JA; Trapani JA. 2006. Cytotoxic T lymphocytes from cathepsin B-deficient mice survive normally in vitro and in vivo after encountering and killing target cells. J Biol Chem 281(41):30485-91. [PubMed: 16914553]  [MGI Ref ID J:117187]

Baskin-Bey ES; Canbay A; Bronk SF; Werneburg N; Guicciardi ME; Nyberg SL; Gores GJ. 2005. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol 288(2):G396-402. [PubMed: 15472011]  [MGI Ref ID J:96164]

Bernhardt A; Kuester D; Roessner A; Reinheckel T; Krueger S. 2010. Cathepsin X-deficient gastric epithelial cells in co-culture with macrophages: characterization of cytokine response and migration capability after Helicobacter pylori infection. J Biol Chem 285(44):33691-700. [PubMed: 20736174]  [MGI Ref ID J:166782]

Buhler A; Berger S; Bengsch F; Martin G; Han H; Vierkotten S; Pielen A; Boehringer D; Schlunck G; Fauser S; Agostini HT; Reinheckel T; Stahl A. 2013. Cathepsin proteases promote angiogenic sprouting and laser-induced choroidal neovascularisation in mice. Exp Eye Res 115:73-8. [PubMed: 23800510]  [MGI Ref ID J:210411]

Byrne SM; Aucher A; Alyahya S; Elder M; Olson ST; Davis DM; Ashton-Rickardt PG. 2012. Cathepsin B controls the persistence of memory CD8+ T lymphocytes. J Immunol 189(3):1133-43. [PubMed: 22745374]  [MGI Ref ID J:189782]

Canbay A; Guicciardi ME; Higuchi H; Feldstein A; Bronk SF; Rydzewski R; Taniai M; Gores GJ. 2003. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 112(2):152-9. [PubMed: 12865404]  [MGI Ref ID J:117983]

Chang SH; Kanasaki K; Gocheva V; Blum G; Harper J; Moses MA; Shih SC; Nagy JA; Joyce J; Bogyo M; Kalluri R; Dvorak HF. 2009. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res 69(10):4537-44. [PubMed: 19435903]  [MGI Ref ID J:148475]

Conus S; Perozzo R; Reinheckel T; Peters C; Scapozza L; Yousefi S; Simon HU. 2008. Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation. J Exp Med 205(3):685-98. [PubMed: 18299403]  [MGI Ref ID J:133082]

Czibere L; Baur LA; Wittmann A; Gemmeke K; Steiner A; Weber P; Putz B; Ahmad N; Bunck M; Graf C; Widner R; Kuhne C; Panhuysen M; Hambsch B; Rieder G; Reinheckel T; Peters C; Holsboer F; Landgraf R; Deussing JM. 2011. Profiling trait anxiety: transcriptome analysis reveals cathepsin B (ctsb) as a novel candidate gene for emotionality in mice. PLoS One 6(8):e23604. [PubMed: 21897848]  [MGI Ref ID J:176144]

Dev A; Byrne SM; Verma R; Ashton-Rickardt PG; Wojchowski DM. 2013. Erythropoietin-directed erythropoiesis depends on serpin inhibition of erythroblast lysosomal cathepsins. J Exp Med 210(2):225-32. [PubMed: 23319700]  [MGI Ref ID J:195889]

Duewell P; Kono H; Rayner KJ; Sirois CM; Vladimer G; Bauernfeind FG; Abela GS; Franchi L; Nunez G; Schnurr M; Espevik T; Lien E; Fitzgerald KA; Rock KL; Moore KJ; Wright SD; Hornung V; Latz E. 2010. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464(7293):1357-61. [PubMed: 20428172]  [MGI Ref ID J:159453]

Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W. 2006. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 21(9):1399-408. [PubMed: 16939398]  [MGI Ref ID J:128089]

Felbor U; Kessler B; Mothes W; Goebel HH; Ploegh HL; Bronson RT; Olsen BR. 2002. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc Natl Acad Sci U S A 99(12):7883-8. [PubMed: 12048238]  [MGI Ref ID J:77103]

Friedrichs B; Tepel C; Reinheckel T; Deussing J; von Figura K; Herzog V; Peters C; Saftig P; Brix K. 2003. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest 111(11):1733-45. [PubMed: 12782676]  [MGI Ref ID J:83877]

Gocheva V; Wang HW; Gadea BB; Shree T; Hunter KE; Garfall AL; Berman T; Joyce JA. 2010. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24(3):241-55. [PubMed: 20080943]  [MGI Ref ID J:156936]

Gocheva V; Zeng W; Ke D; Klimstra D; Reinheckel T; Peters C; Hanahan D; Joyce JA. 2006. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20(5):543-56. [PubMed: 16481467]  [MGI Ref ID J:105935]

Gounaris E; Tung CH; Restaino C; Maehr R; Kohler R; Joyce JA; Plough HL; Barrett TA; Weissleder R; Khazaie K. 2008. Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS ONE 3(8):e2916. [PubMed: 18698347]  [MGI Ref ID J:140593]

Gross O; Poeck H; Bscheider M; Dostert C; Hannesschlager N; Endres S; Hartmann G; Tardivel A; Schweighoffer E; Tybulewicz V; Mocsai A; Tschopp J; Ruland J. 2009. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 459(7245):433-6. [PubMed: 19339971]  [MGI Ref ID J:148538]

Guicciardi ME; Deussing J; Miyoshi H; Bronk SF; Svingen PA; Peters C; Kaufmann SH; Gores GJ. 2000. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 106(9):1127-37. [PubMed: 11067865]  [MGI Ref ID J:77596]

Guicciardi ME; Miyoshi H; Bronk SF; Gores GJ. 2001. Cathepsin B Knockout Mice Are Resistant to Tumor Necrosis Factor-alpha-Mediated Hepatocyte Apoptosis and Liver Injury : Implications for Therapeutic Applications. Am J Pathol 159(6):2045-54. [PubMed: 11733355]  [MGI Ref ID J:72935]

Ha SD; Martins A; Khazaie K; Han J; Chan BM; Kim SO. 2008. Cathepsin B is involved in the trafficking of TNF-alpha-containing vesicles to the plasma membrane in macrophages. J Immunol 181(1):690-7. [PubMed: 18566436]  [MGI Ref ID J:137392]

Henningsson F; Yamamoto K; Saftig P; Reinheckel T; Peters C; Knight SD; Pejler G. 2005. A role for cathepsin E in the processing of mast-cell carboxypeptidase A. J Cell Sci 118(Pt 9):2035-42. [PubMed: 15860733]  [MGI Ref ID J:98827]

Hook VY; Kindy M; Reinheckel T; Peters C; Hook G. 2009. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun 386(2):284-8. [PubMed: 19501042]  [MGI Ref ID J:151423]

Im E; Venkatakrishnan A; Kazlauskas A. 2005. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell 16(8):3488-500. [PubMed: 15901832]  [MGI Ref ID J:101756]

Kalantari P; DeOliveira RB; Chan J; Corbett Y; Rathinam V; Stutz A; Latz E; Gazzinelli RT; Golenbock DT; Fitzgerald KA. 2014. Dual engagement of the NLRP3 and AIM2 inflammasomes by plasmodium-derived hemozoin and DNA during malaria. Cell Rep 6(1):196-210. [PubMed: 24388751]  [MGI Ref ID J:206874]

Koike M; Shibata M; Waguri S; Yoshimura K; Tanida I; Kominami E; Gotow T; Peters C; von Figura K; Mizushima N; Saftig P; Uchiyama Y. 2005. Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (batten disease). Am J Pathol 167(6):1713-28. [PubMed: 16314482]  [MGI Ref ID J:103645]

Lalanne AI; Moraga I; Hao Y; Pereira JP; Alves NL; Huntington ND; Freitas AA; Cumano A; Vieira P. 2010. CpG inhibits pro-B cell expansion through a cathepsin B-dependent mechanism. J Immunol 184(10):5678-85. [PubMed: 20400700]  [MGI Ref ID J:160995]

Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL. 2005. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice. J Immunol 174(11):7066-74. [PubMed: 15905550]  [MGI Ref ID J:99005]

Mercure C; Lacombe MJ; Khazaie K; Reudelhuber TL. 2010. Cathepsin B is not the processing enzyme for mouse prorenin. Am J Physiol Regul Integr Comp Physiol :. [PubMed: 20164204]  [MGI Ref ID J:159704]

Miller G; Matthews SP; Reinheckel T; Fleming S; Watts C. 2011. Asparagine endopeptidase is required for normal kidney physiology and homeostasis. FASEB J 25(5):1606-17. [PubMed: 21292981]  [MGI Ref ID J:172774]

Mueller-Steiner S; Zhou Y; Arai H; Roberson ED; Sun B; Chen J; Wang X; Yu G; Esposito L; Mucke L; Gan L. 2006. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51(6):703-14. [PubMed: 16982417]  [MGI Ref ID J:113649]

Nepal RM; Mampe S; Shaffer B; Erickson AH; Bryant P. 2006. Cathepsin L maturation and activity is impaired in macrophages harboring M. avium and M. tuberculosis. Int Immunol 18(6):931-9. [PubMed: 16636015]  [MGI Ref ID J:109136]

Nepal RM; Vesosky B; Turner J; Bryant P. 2008. DM, but not cathepsin L, is required to control an aerosol infection with Mycobacterium tuberculosis. J Leukoc Biol 84(4):1011-8. [PubMed: 18591414]  [MGI Ref ID J:140231]

Ohkouchi S; Shibata M; Sasaki M; Koike M; Safig P; Peters C; Nagata S; Uchiyama Y. 2013. Biogenesis and proteolytic processing of lysosomal DNase II. PLoS One 8(3):e59148. [PubMed: 23516607]  [MGI Ref ID J:199384]

Pluger EB; Boes M; Alfonso C; Schroter CJ; Kalbacher H; Ploegh HL; Driessen C. 2002. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol 32(2):467-76. [PubMed: 11813165]  [MGI Ref ID J:107213]

Rocken C; Fandrich M; Stix B; Tannert A; Hortschansky P; Reinheckel T; Saftig P; Kahne T; Menard R; Ancsin JB; Buhling F. 2006. Cathepsin protease activity modulates amyloid load in extracerebral amyloidosis. J Pathol 210(4):478-87. [PubMed: 17068745]  [MGI Ref ID J:116135]

Sevenich L; Schurigt U; Sachse K; Gajda M; Werner F; Muller S; Vasiljeva O; Schwinde A; Klemm N; Deussing J; Peters C; Reinheckel T. 2010. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A 107(6):2497-502. [PubMed: 20133781]  [MGI Ref ID J:157541]

Shen L; Sigal LJ; Boes M; Rock KL. 2004. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21(2):155-65. [PubMed: 15308097]  [MGI Ref ID J:93590]

Steenhuis P; Froemming J; Reinheckel T; Storch S. 2012. Proteolytic cleavage of the disease-related lysosomal membrane glycoprotein CLN7. Biochim Biophys Acta 1822(10):1617-28. [PubMed: 22668694]  [MGI Ref ID J:188065]

Sun L; Wu Z; Baba M; Peters C; Uchiyama Y; Nakanishi H. 2010. Cathepsin B-dependent motor neuron death after nerve injury in the adult mouse. Biochem Biophys Res Commun 399(3):391-5. [PubMed: 20673755]  [MGI Ref ID J:164910]

Sun L; Wu Z; Hayashi Y; Peters C; Tsuda M; Inoue K; Nakanishi H. 2012. Microglial Cathepsin B Contributes to the Initiation of Peripheral Inflammation-Induced Chronic Pain. J Neurosci 32(33):11330-11342. [PubMed: 22895716]  [MGI Ref ID J:187721]

Unno T; Wakamori M; Koike M; Uchiyama Y; Ishikawa K; Kubota H; Yoshida T; Sasakawa H; Peters C; Mizusawa H; Watase K. 2012. Development of Purkinje cell degeneration in a knockin mouse model reveals lysosomal involvement in the pathogenesis of SCA6. Proc Natl Acad Sci U S A 109(43):17693-8. [PubMed: 23054835]  [MGI Ref ID J:190729]

Vasiljeva O; Korovin M; Gajda M; Brodoefel H; Bojic L; Kruger A; Schurigt U; Sevenich L; Turk B; Peters C; Reinheckel T. 2008. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 27(30):4191-9. [PubMed: 18345026]  [MGI Ref ID J:138505]

Vasiljeva O; Papazoglou A; Kruger A; Brodoefel H; Korovin M; Deussing J; Augustin N; Nielsen BS; Almholt K; Bogyo M; Peters C; Reinheckel T. 2006. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 66(10):5242-50. [PubMed: 16707449]  [MGI Ref ID J:109056]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2140.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We willfulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2782.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We willfulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

General Supply Notes

Control Information

  Control
   001976 NOD/ShiLtJ
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.6)